Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA)’s share price was up 3.8% during trading on Thursday . The company traded as high as $3.32 and last traded at $3.29, with a volume of 62,420 shares trading hands. The stock had previously closed at $3.17.

A number of equities analysts have recently commented on DRNA shares. Leerink Swann restated a “buy” rating on shares of Dicerna Pharmaceuticals in a research report on Thursday, June 30th. Stifel Nicolaus cut their price objective on shares of Dicerna Pharmaceuticals from $16.00 to $13.00 and set a “buy” rating for the company in a research report on Thursday, June 30th. Cowen and Company restated a “buy” rating on shares of Dicerna Pharmaceuticals in a research report on Friday, August 5th. Chardan Capital cut their price objective on shares of Dicerna Pharmaceuticals from $5.00 to $4.00 and set a “neutral” rating for the company in a research report on Thursday, June 30th. Finally, Zacks Investment Research upgraded shares of Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating and set a $3.75 price objective for the company in a research report on Thursday, May 12th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $11.85.

The company’s market cap is $71.50 million. The firm’s 50 day moving average price is $3.28 and its 200 day moving average price is $4.42.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last issued its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.75) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.84) by $0.09. On average, analysts anticipate that Dicerna Pharmaceuticals Inc. will post ($3.21) EPS for the current fiscal year.

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.